CADL Archived Articles
Candel Therapeutics' Resilience Shines Through with Landmark Prostate Cancer Trial Success
Published on March 15, 2025
Candel Therapeutics (NASDAQ:CADL): A Pioneer in Multimodal Biological Immunotherapies
Published on November 30, 2024
Candel Therapeutics, Inc. (CADL): Advancing Viral Immunotherapies to Fight Cancer
Published on September 24, 2024